🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

criticalcarescience.org.br/artigo/detalhe… DEFENDER study design has just been published. Results coming Q1/2024. Stay tuned!! Otavio Berwanger Fernando Zampieri Luciano Cesar Pontes Azevedo Ary Serpa Neto Lucas Petri Damiani

AWAITING THE VERDICT! Introduce or not statins for primary #prevention in older people. What about those classified as #frail? Look at our editorial JAGS agsjournals.onlinelibrary.wiley.com/doi/10.1111/jg… about brilliant work of Orkaby et al. Nicholas Pajewski Caio de Assis Moura Tavares #Geriatrics #Cardiology

Saint Luke's Mid America Heart Institute is proud to announce we randomized first patient in REDEFINE-HF, an international, randomized, placebo-controlled, event-driven trial of finerenone for the treatment hospitalized heart failure patients with HFmrEF/HFpEF. classic.clinicaltrials.gov/ct2/show/NCT06…

Exciting news! The DEFENDER trial results will be presented as an LBCT at the upcoming CCR meeting in June. Stay tuned! mail.criticalcarereviews.com/meetings/ccr24… Otavio Berwanger Fernando Zampieri Luciano Cesar Pontes Azevedo Lucas Petri Damiani

Muhammad Shariq Usman Javed Butler The Lancet Diabetes & Endocrinology Dr. Deepak L. Bhatt Shahzeb Khan UTSW Internal Medicine Chiefs Great meta-analysis- congrats! It seems to me that the saga continues. You will hear from our DEFENDER trial in critically-ill patients in a few weeks and I believe SGLT-2 inhibitors also need to be tested for heart failure prevention in a broader population at risk for HF.

Our DEFENDER trial just published in JAMA. Great team work! Dapagliflozin for Critically Ill Patients With Acute Organ Dysfunction: The DEFENDER Randomized Clinical Trial Caio de Assis Moura Tavares Fernando Zampieri ⁦Luciano Cesar Pontes Azevedo⁩ jamanetwork.com/journals/jama/…

Today I had the real honor to represent the whole #DEFENDERtrial team and present our results together with Fernando Zampieri in the incredible #CCR24 meeting with an amazing team of panellists. Best part came afterwards - when I realized my family was following it from BR at 5am 😂

A testament to the amazingly strong safety profile of #SGLT2i, even in this critically ill #RCT population. No significant difference in AEs vs placebo In fact, in #DEFENDER, numerically fewer total SAEs and infections w/ #SGLT2i, compared with placebo. Gregg Fonarow MD Muthu Vaduganathan

#DEFENDER was published in JAMA last Friday. 507 critically ill patients were randomized to dapagliflozin 10 mg for a fortnight or until ICU discharge. We used the Win Ratio approach but many other methods could have been used. A thread. (+) jamanetwork.com/journals/jama/…

Last Friday, Fernando Zampieri & Caio de Assis Moura Tavares presented the results of the #DEFENDERtrial at #CCR24 Paper - JAMA - jamanetwork.com/journals/jama/… Editorial - JAMA - jamanetwork.com/journals/jama/… from @Lennie333 & Hernando Gómez

Massimiliano Ruscica Stefano Carugo AtheroMad Hope ongoing trials like EVOLVE-MI show the clinical correspondence to changes in plaque biology! Amgen 🧪🔬🧬 Otavio Berwanger Caio de Assis Moura Tavares Marc Bonaca MD MPH

We are proud to announce the first patient enrollment today at Saint Luke's Mid America Heart Institute for the fourth and final clinical trial (FINALITY-HF) of the larger MOONRAKER program on finerenone in heart failure. FINEARTS-HF, the first in the finerenone program,

Great night with visiting friends!! Patricia Pedro Lemos Mikhail Kosiborod Marc Bonaca MD MPH

Great to have discussed innovative and digital trials at The Pulmonary Vascular Research Institute in Rio! Grateful to have Otavio Berwanger as a mentor—a true leader in this field!

Empagliflozin in Patients With Type 2 Diabetes Undergoing On-Pump CABG: The POST-CABGDM Randomized Clinical Trial diabetesjournals.org/care/article-a… Our single-center study is finally out—another piece of evidence pointing toward kidney protection with SGLT2 inhibitors.

Our IPDMA of JAK inhibitors in pts hospitalized with COVID-19 is out! JAKi were associated with a reduction in mortality. Otavio Berwanger Patricia Alain Amstutz🇨🇭🇱🇸 . Must-read editorial by Andre Kalil, MD MPH thelancet.com/journals/lanre…

Current evidence and future perspectives in HFpEF therapy. #HREV Josephine Harrington, MD Caio de Assis Moura Tavares Andrew P. Ambrosy, MD, MPH orlyvardeny Andrew J Sauer MD Marc Bonaca MD MPH CPC Clinical Research link.springer.com/article/10.100…

Our DEFENDER subanalysis is out! Important insights into acute effects of using sglt2i in the ICU Fernando Zampieri Luciano Cesar Pontes Azevedo Otavio Berwanger rdcu.be/ewiku